Literature DB >> 20156559

The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury.

Angel Arevalo-Martin1, Daniel Garcia-Ovejero, Eduardo Molina-Holgado.   

Abstract

A series of pathological events secondary to spinal cord injury (SCI) contribute to the spread of the damage, which aggravates neurological deficits. Here we report that a single dose of the neuroprotective endocannabinoid 2-arachidonoyl glycerol (2-AG) administered early after SCI reduces lesion expansion, which was prevented by simultaneous blockade of both CB1 and CB2 receptors but not by blockade of either receptor alone. Treatment with 2-AG also preserves the white matter around the epicenter of the injury. Moreover, in the preserved white matter, 2-AG protects myelin from damage and reduces oligodendrocyte loss. In addition to these protective actions at the epicenter region, 2-AG also inhibits the myelin damage and delayed oligodendrocyte loss induced at 10mm from the epicenter. Interestingly, the early protective action of 2-AG is maintained 28 days after injury, when the lesion size is still smaller and the preservation of white matter is better in 2-AG-treated animals. Therefore, our results show that 2-AG protects from the expansion of the lesion and white matter damage, which suggest that this endogenous cannabinoid may be useful as a protective treatment for acute SCI. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156559     DOI: 10.1016/j.nbd.2010.02.002

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  17 in total

1.  PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Authors:  L Mestre; M Redondo; F J Carrillo-Salinas; J A Morales-García; S Alonso-Gil; A Pérez-Castillo; C Gil; A Martínez; C Guaza
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

2.  2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Authors:  Ana Feliú; Itziar Bonilla Del Río; Francisco Javier Carrillo-Salinas; Gloria Hernández-Torres; Leyre Mestre; Nagore Puente; Silvia Ortega-Gutiérrez; Maria L López-Rodríguez; Pedro Grandes; Miriam Mecha; Carmen Guaza
Journal:  J Neurosci       Date:  2017-07-27       Impact factor: 6.167

Review 3.  Remote neurodegeneration: multiple actors for one play.

Authors:  Maria Teresa Viscomi; Marco Molinari
Journal:  Mol Neurobiol       Date:  2014-01-19       Impact factor: 5.590

4.  Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease.

Authors:  Jian Zhang; Mei Hu; Zhaoqian Teng; Ya-Ping Tang; Chu Chen
Journal:  J Neurosci       Date:  2014-11-05       Impact factor: 6.167

5.  Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain.

Authors:  Chia-Shan Wu; Christopher P Jew; Hui-Chen Lu
Journal:  Future Neurol       Date:  2011-07-01

6.  Progesterone reduces secondary damage, preserves white matter, and improves locomotor outcome after spinal cord contusion.

Authors:  Daniel Garcia-Ovejero; Susana González; Beatriz Paniagua-Torija; Analía Lima; Eduardo Molina-Holgado; Alejandro F De Nicola; Florencia Labombarda
Journal:  J Neurotrauma       Date:  2014-05-01       Impact factor: 5.269

Review 7.  Endocannabinoids in synaptic plasticity and neuroprotection.

Authors:  Jian-Yi Xu; Chu Chen
Journal:  Neuroscientist       Date:  2014-02-25       Impact factor: 7.519

8.  Endocannabinoid 2-arachidonylglycerol protects primary cultured neurons against homocysteine-induced impairments in rat caudate nucleus through CB1 receptor.

Authors:  Manman Dong; Yongli Lu; Yunhong Zha; Hongwei Yang
Journal:  J Mol Neurosci       Date:  2014-07-11       Impact factor: 3.444

9.  Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease.

Authors:  Rongqing Chen; Jian Zhang; Yan Wu; Dongqing Wang; Guoping Feng; Ya-Ping Tang; Zhaoqian Teng; Chu Chen
Journal:  Cell Rep       Date:  2012-11-01       Impact factor: 9.423

10.  Activation of cannabinoid receptor 2 inhibits experimental cystitis.

Authors:  Zun-Yi Wang; Peiqing Wang; Dale E Bjorling
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-20       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.